UNSPSC 51372007: Etorphine

This classification denotes an opioid receptor agonist with the molecular formula C25H33NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42M2Y6NU9O, chemically known as 6,7,8,14-tetrahydro-7alpha-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine but generally known as etorphine, which bears US NIH Compound Identifier 26721. European Medicines Agency schedules Etorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07339MIG.

UNSPSC 51372007 Etorphine is a Commodity code that captures pharmaceutical products used in emergency medical and community health interventions, though recent state and local procurement activity under this code shows minimal alignment with the code's nominal pharmaceutical scope. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS posted June 30, 2026—solicits naloxone and drug deactivation systems for community health initiatives rather than etorphine itself, suggesting either a classification mismatch in the issuing jurisdiction's tagging or limited actual procurement volume under the etorphine code proper. State and local health departments and county government public-health divisions appear to be the primary issuing bodies when activity does occur under this code, though the recent-opportunities block contains no evidence of repeat buyers or sustained procurement patterns.

Seminole County, Florida represents the only jurisdiction with a recent opportunity logged under this code. The IFB seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, with response due July 26, 2023—a date that has passed. Vendors must include shipping and delivery costs, comply with drug-free workplace and E-Verify requirements, maintain workers' compensation and liability insurance, and meet federal compliance standards tied to potential FEMA funding. The contract structure provides for a two-year initial term with one-year renewal option and includes a three-month probationary termination clause. No explicit set-aside designations are noted. The sparse activity under this code suggests limited state and local procurement of etorphine specifically; procurement professionals should verify whether opportunities are being tagged accurately or whether actual demand for this pharmaceutical lies elsewhere in the UNSPSC taxonomy.